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Purpose of review—To describe progress and challenges to elimination of mother-to-child HIV 
transmission (EMCT) in high-income countries.
Recent findings—Despite ongoing declines in the number of perinatally HIV-infected infants 
in most high-income countries, the number of HIV-infected women delivering may be increasing, 
accompanied by apparent changes in this population, including higher percentages with 
antiretroviral “pre-treatment” (with possible antiretroviral resistance), other co-infections, mental 
health diagnoses, and recent immigration. The impact of antiretroviral resistance on mother-to-
child transmission is yet to be defined. A substantial minority of infant HIV acquisitions occur in 
the context of maternal acute HIV infection during pregnancy. Some infant infections occur after 
pregnancy, e.g., by premastication of food, or breastfeeding (perhaps by an uninfected woman 
who acquires HIV while breastfeeding).
Summary—The issues of EMCT are largely those of providing proper care for HIV-infected 
women. Use of combination antiretroviral therapy by increasing proportions of the infected 
population may function as a structural intervention important to achieving this goal. Providers 
and public health systems need to be alert for HIV-serodiscordant couples in which the woman is 
uninfected and for changes in the population of HIV-infected pregnant women. Accurate data 
about HIV-exposed pregnancies is vital to monitor progress toward EMCT.
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Elimination of mother-to-child HIV transmission (EMCT) has been adopted as a goal in 
high-income countries such as the United States (US) [1] and the countries of Europe [2], 
and also in less-resourced countries [3]with much higher incidences of mother-to-child 
transmission (MTCT) of HIV. In the US, the achievements of the past two decades leading 
to this goal are the result of the following:1) early and ongoing clinical research, 2) 
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proactive public health policies and recommendations, 3) dedicated funding for clinical care 
(including laboratory monitoring, antiretrovirals [ARV] for prophylaxis and treatment, and 
alterations in obstetric practice), 4) case management services through Medicaid and the 
federal Ryan White Program and, 5) federal and state public health support for surveillance 
for MTCT, HIV testing, and public education. Ongoing cases of MTCT continue, however, 
and will challenge clinicians and public health professionals to adapt as the population of 
HIV-infected pregnant women changes. If at one time the emphasis was on young women 
with untreated HIV infection diagnosed during pregnancy, the contemporary population also 
includes substantial numbers of older women who may have knowledge of their HIV status, 
experience with ARV's, viral strains resistant to antiretroviral therapy (ART), viral co-
infections, or recently immigrated. After an epidemic of more than 30 years, after nearly 20 
years of effective prevention of MTCT (PMTCT) and treatment of HIV, this paper describes 
changes in the population of pregnant HIV-infected women (Table 1) in the US and other 
high-income countries, as well as challenges (Table 2) for the health-care and public health 
systems which will affect EMCT in the years to come.
Numbers of cases
HIV-infected infants
The United States and nearly all western European countries reportvery low annual numbers 
of perinatally infected infants and children [4-8]. The numbers of infected children in the 
World Health Organization's European region, however, increased from 347 to 494 between 
2004 and 2011, largely because of the number of infections inits eastern and central sub-
regions [9].
Among HIV-infected children in the US and Europe, birth in lesser-resourced countries, 
most often sub-Saharan Africa, is becoming more frequent. During 2007-2010, foreign-birth 
was reported for 33% (295/884) of HIV-infected children diagnosed with HIV in the US 
[10], and an even greater proportion of foreign birth was reported for infected children in 
France and in the United Kingdom (UK), at 60% and 73%, respectively [6, 11].
HIV-infected pregnant women
In several resource-rich countries, an increase in the number of HIV-infected pregnant 
women delivering annually has been reported in the last decade [5, 12-14]. Repeat 
pregnancies among HIV-infected women are increasing in European countries [15-17]. The 
live-birth rate of HIV-infected women in the US increased 150% from the era before highly 
active antiretroviral therapy (HAART) (pre-HAART era, 1994-1995) to the HAART era 
(2001-2002) [18], while, on the other hand, pregnancy rates between 1994 and 2009 in HIV-
infected women were approximately half those in HIV-uninfected women in the US [19, 
20].
Characteristics of the population of HIV-infected pregnant women
Injection drug use among HIV-infected pregnant women appears to be declining, from 11% 
during 2000-2003 to 8% during 2005-2008 in U.S. Enhanced Perinatal Surveillance (EPS); 
use of any illicit drugs declined from 20% to 11% in the same periods [21, 22]. Another US 
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study, the Surveillance Monitoring of ART Toxicities (SMARTT) cohort reported ‘hard 
drug use’ by 3% of women in 2007-2010 [23], while also reporting positive behavioral 
screens for mental disorder (mainly post-traumatic stress disorder) or substance abuse in 
35% compared to 26% in the general population [24].
Immigrants from lesser-resourced countries account for an increasing proportion of HIV-
exposed deliveries, including 78.5% of infected women delivering in the UK during 
2000-2009 [15] and 60% in Canada during 2007-2009 [25]. Among mothers of HIV-
infected infants reported to US National HIV Surveillance during 2003-2007, 21% were 
born in countries other than the US [26]. The annual percentage of HIV-infected pregnant 
women born in Africa and delivering was 24-78% in several western European countries 
during the past decade [7, 12, 27, 28]. Immigrant women were at some risk of less frequent 
uptake of PMTCT interventions, specifically, accessing prenatal care and ARV initiation 
[27, 29].
An estimated 140,000 HIV-serodiscordant heterosexual couples reside in the US [30], but 
whether that number or its proportion of HIV-infected persons is changing is unknown. It is 
known that many HIV-infected women have HIV-uninfected partners. Of 181 HIV-infected 
US women of childbearing age, 62% had negative partners and 11% had partners of 
unknown status [31]. In France, among HIV-infected individuals, 41.5% of men and 43.6% 
of women had partners of unknown or negative status [32]. The patterns of serodiscordance 
offer different opportunities for prevention of HIV MCT, which become more relevant as 
the population's desire to conceive and bear children increases. One US study of 181 women 
of childbearing age reported that 59% desired children, of whom 66% intend to have 
children [31]. Studies from Canada and the UK have reported similar findings [33, 34]. Of 
HIV-infected persons in France, 20% of men and 33% of women expected to have children 
[32]. Finally, a study of perinatally infected females of childbearing age found that 70% 
intended to have children [35]. Safer conception for HIV-discordant couples is being made 
possible through the use of assisted reproductive technology [30, 36]—e.g., artificial 
insemination of an HIV positive woman, or so-called ‘sperm washing’, with intrauterine 
insemination or in vitro fertilization—and antiretrovirals for pre-exposure prophylaxis [37] 
or treatment as prevention [38]. It remains to be seen whether these approaches will lead to 
an increase in the annual number of HIV-exposed infants.
Perinatal Prevention Cascade—uptake of elements
In the US, MTCT has been organized around the perinatal HIV prevention cascade (see 
Figure), which begins with primary prevention of HIV infection and preconception care of 
women known to be infected prior to pregnancy a percentage which appears to be increasing 
[21, 22]. While more women may thus have opportunity to maximize their HIV care and 
plans for pregnancy, there is a paucity of data about how many HIV-infected women acquire 
such preconception care. One US study (2008-2010) reported that 50.6% of sexually active 
HIV-infected women had spoken with a provider within the past year about contraception 
plans [39]. At least one unplanned pregnancy after learning her HIV diagnosis was reported 
by 88% in a study of US women [40]. Maternal diagnosis was established before pregnancy 
in 60% and 68% of cases during 2000-2003 and 2005-2008, respectively [21, 22]. In Italy, 
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32.9% of HIV-infected pregnant women's diagnoses were made during pregnancy in 2008, a 
figure unchanged over the preceding decade [28]. In the US, once a diagnosis is made 
prenatal care was received by a large percentage (88% in 2000-2003and 90% in 2005-2008) 
[21, 22]. In those periods, use of prenatal, natal (labor and delivery) and post-natal ARV use 
increased [21, 22]. In SMARTT during 2007-2011, effective combination antiretroviral 
therapy (cART) use was reported by 85% of women in the ‘dynamic’ cohort [23]. Similar 
high rates of cART use have been seen in several European countries [7, 28, 41], where its 
use is frequently reported at the time of conception [16, 41]. Though ARV resistance has 
been recognized in maternal and infant viral strains, it is not clear that the proportion of 
affected individuals has changed, nor is the effect on MCT clear [42]. Adherence to ARV's 
during pregnancy often exceeds that in the post-partum period [43, 44]. Uptake of PMTCT 
interventions and viral load suppression–but not MCT rate—are highly associated with a 
woman's disclosure of her diagnosis to her partner [45].
Maternal viral suppression appears to be increasingly common in recent years. In SMARTT, 
only 15% in the ‘dynamic’ cohort had VL > 1000 copies/ml [23]. In several European 
cohorts, viral RNA was frequently undetectable at the time of delivery: 65% in the European 
Collaborative Study [46]; 65% in the French Perinatal Cohort [17]; 80.9% in Italy [28]; and 
77% in London [47].
Mode of delivery of infants to HIV-infected women in the US was by elective Cesarean-
section in 36% during 2000-2003 [21] and 40% during 2005-2008 [22]. While the Cesarean-
section rate has been higher in Europe [28, 46], the rates have declined in UK/Ireland, from 
a peak of 66.4% in 1999to 50% in 2006 [12]. Similarly, in Spain the elective Cesarean 
delivery rate was 57.6% in 2000-3 and 46.5% in 2004-7 [7].
“Other” opportunities for HIV MCT—There are several opportunities for MTCT which 
don't fit neatly into, or whose issues transcend, the list of prevention interventions—and 
their converse, missed opportunities— in the perinatal prevention cascade. Women with 
acute HIV-infection—that is, women who seroconvert to HIV-positive status—during 
pregnancy or breastfeeding are more likely to transmit HIV to their infants, mainly because 
of higher HIV VL's which occur, albeit transiently, during acute HIV infections. Such 
infections are typically the result of partnerships of an HIV-infected man and HIV-
uninfected woman. That number is not precisely known, but it is vital that individuals be 
alerted to the additional risk attendant to such partnerships. The proportion of perinatal HIV 
transmissions which occur under these conditions in recent years is 8% in the U.S. among 
cases reported to EPS during 2005-2010 [48], 11.5% in the UK audit of transmissions which 
occurred during 2002-2005 [49], and 14% in cases reported to New York State during 
2002-2006 [50]. As overall MCT rates decline among women with established HIV 
diagnoses, it is possible that those with acute infection may comprise an increasing 
proportion of MCT. It has been suggested that the rate of acute infection in adolescent 
females may behigh because of the high HIV incidence among adolescent males [51], some 
of whom have sex with both males and females. Among HIV-infected females of 
reproductive age is an increasing number who acquired infection perinatally [52]. Though 
these women may deliver prematurely or require Cesarean delivery more frequently, they 
appear to transmit HIV to their infants at a rate similar to other HIV-infected women [52]. 
Nesheim et al. Page 4









Finally, there are the so-called “late” perinatal transmissions, which may result from infants 
ingesting “premasticated” food, from being breastfed by an HIV-infected woman, or from 
behaviors which are difficult to characterize; some of these infants, though born to HIV-
infected women, have repeatedly negative nucleic acid amplification tests (NAAT) before 
they have a NAAT result which establishes their diagnosis [53].
Challenges for EMCT
The annual number of HIV-infected infants born in the US and most other high-income 
countries is decreasing. Though the numbers of deliveries by HIV-infected pregnant women 
appears to be increasing, at least in the US, this trend is not the result of increasing incidence 
among women, as HIV incidence is actually decreasing [54]. The increased number of 
deliveries appears to be the result of improved survival and overall well-being, accompanied 
by increasing desire to conceive and increasing numbers of women with ‘repeat’ 
pregnancies. Whether the number of HIV-exposed pregnancies will further increase as the 
availability of assisted reproductive technologies increases—and how such technologies will 
change PMTCT—remains to be seen. The evident connection between survival and ART 
means that increasing numbers of women will be ART-experienced when they conceive. It 
can be anticipated that recent ART guidelines, which recommend treatment for all HIV-
infected persons [55], when implemented, will constitute an important structural 
intervention for EMCT, leading to an increasing proportion with viral suppression among 
women of childbearing age. This experience leads not only to increased prenatal ARV 
exposure, but also the possibility of an increasing prevalence of ARV-resistant HIV, which 
in turn could result in more women being on second- and third-line regimens whose 
effectiveness may differ So far, MTCT does not appear to be substantially affected by ARV-
resistance [42]. Additional antiviral exposure—as well as additional maternal morbidity--in 
this population may occur as a result of maternal co-infection with other viruses, notably 
hepatitis B and hepatitis C viruses. Though immigrant HIV-infected women of childbearing 
age comprise an increasing percentage in many resource-rich countries, their PMTCT 
problems relate more to health care access and utilization (e.g., timely diagnosis, linkage to 
and retention in primary and prenatal care) than to biomedical issues (e.g., resistant virus, 
adherence).
In the US, most of the ongoing mother-to-childtransmissions are apparently attributable to 
incomplete uptake of elements of the Perinatal Prevention Cascade, e.g., identification of 
HIV-infected women and effective retention of them in care [56]. It is likely that many of 
such transmissions are from women who are extremely difficult to reach, for reasons in 
addition to illicit drug abuse, reasons which include the substantial degree of poverty [57] 
and mental health problems in the population. The expansion in medical care access in the 
U.S. anticipated from the Affordable Care Act may mitigate some of poverty's effects, but it 
can be predicted that the social instability and segregation associated with poverty will 
continue to aggravate problems of access. Indeed, in this era of low MCT rates, as each 
transmission's specific characteristics take on heightened importance, it remains important to 
review cases, with the goal of changing the local system in ways that may prevent further 
transmissions and improve the care of HIV-infected women to optimize their health prior to
—and between—pregnancies, as well as to prevent unwanted pregnancies. The Framework 
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for EMCT [1] incorporates Case Review and Community Action as one of its key 
components, as the Fetal-Infant Mortality Review—HIV (FIMR-HIV) Prevention Program. 
The US Centers for Disease Control and Prevention includes FIMR-HIV among activities 
encouraged by its prevention grantees. These reviews have identified issues of domestic 
violence and maternal mental health diagnoses [58]. FIMR-HIV has also recognized the 
dramatic effect on women—including depression and decreased linkage to care and 
medication adherence—when they lose custody of children after birth.
Conclusion
It will remain a challenge for public health institutions to commit new funds to PMTCT as 
the numbers of perinatal cases decline in contrast to the number of adult cases and when 
comparing resource-rich to resource-poor settings. Actionable data on the number of HIV-
infected women delivering, and on the kind of care they receive, is essential for public 
health authorities to monitor EMCT adequately. Support for this can come from state laws 
and policies which advocate “opt-out” HIV testing and encourage perinatal HIV exposure 
reporting. Medical care providers must be made aware of changes in these policies. Vital to 
all of these considerations, however, is the recognition that “elimination” of mother-to-child 
transmission is not a single event, but, rather, is an ongoing process. That process 
necessarily must address the needs of successive annual waves of HIV-infected pregnant 
women as long as there are new cases of HIV in women, underscoring the importance of 
primary prevention and appropriate HIV care for women.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure. Perinatal HIV Prevention Cascade
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Table 1
Perinatal HIV infections in resource-rich countries: numbers, maternal and infant 
characteristics, and preventive interventions




  USA [21, 22] 2000-2003 3.7%
2005-2008 2.2%
  Spain [7] 2000-2003 1.4%
2004-2007 1.8%
 Numbers per year
  USA [4, 8] 2009 151
2010 164
  Europe [9] 2004 347
2011 494
 Incidence per million
  UK [5] - 10
  France [6] 2003-2006 9
HIV-infected women delivering
  USA [14] 2006 8700
  USA (number/1000 person years) [18] 1994-1995 57/1000 PY
2001-2002 142/1000 PY
  UK/Ireland [5, 13] 2006-2010 >1300/yr
2000-2001 3.4%
2008-2009 4.5%
Foreign birth (%) among:
 Infected children
  USA [10] 2007-2010 33%
  France [6] 2006 69%
  UK [11] 2011 73%
 HIV-infected mothers of infected children
  USA [26] 2003-2007 21%
 HIV-infected women delivering
  Canada [25] 2007-2009 60%
  UK/Ireland [12, 15] 1990-1993 43.5%
2004-2006 78.6%
2000-2009 78.5%
  France [27] 1984-1986 12%
2003-2004 64%
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Characteristics and countries Study period Estimates
  Italy [28] 2002 23.9%
2008 45.2%
  Spain [7] 2000-2003 11.4%
2004-2007 22.1%
Characteristics of HIV-Infected women
 Repeat Pregnancies
  UK/Ireland [15] 1997 20.3%
2009 38.6%
  Europe [16] 1989 2%
2003-2004 14%
  France [17] 2009 30%
 Use of cART/HAART at time of conception
  UK [41] 2000-2006 24%
 Adherence during pregnancy and postpartum [43]
  USA (pregnancy) 2001-2005 61%
  USA (post-partum) 2001-2005 44%
 Injection Drug Use
  USA [21, 22] 2000-2003 11%
2005-2008 8%
 Illicit drug use
  USA [21, 22] 2000-2003 20%
2005-2008 11%
 Hard drug use
  USA [23] 2007-2010 3%
 Positive mental health screen & drug use
  USA [24] 2007-2010 35%
 Acute HIV infection during pregnancy or breastfeeding
  USA [48] 2005-2010 8%
  USA (NYS) [50] 2002-2005 14%
  UK [49] 2002-2005 11.5%
 Co-infection w/hepatitis B
  Puerto Rico [59] 1989-1990 12.5%
  USA (Dallas) [60] 1993-2003 1.5%
  Europe [61] 1999-2005 4.9%
  Netherlands [62] 1997-2008 4.9%
  Italy [28] 2000-2008 4%
  UK (London) [47] 2000-2009 4%
  USA (hepatitis B or C) [63] 2006-2010 29%
 Co-infection w/hepatitis C
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Characteristics and countries Study period Estimates
  Puerto Rico [59] 1989-1990 12.5%
  USA [64] 1989-1995 29%
  Italy [28] 2002 29.2%
  USA (Dallas) [60] 1993-2003 4.9%
  Europe [61] 1999-2005 12.3%
  Netherlands [62] 1997-2008 2.1%
  Italy [28] 2008 17.3%
  UK (London) [47] 2000-2009 1.6%
  USA (hepatitis B or C) [63] 2006-2010 29%
 Negative male partner
  USA (n=181) [31] - 62%
  France (n=555) [32] - 43.6%
 Desire/Intention to have children
  USA (n=181) [31]
   Desire - 59%
   Intend - 66%
  USA (n=50) [35]
   Intend 2003-2004 70%
  Canada (n=490) [34]
   Desire 2007-2009 69%
   Intend 2007-2009 56%
  UK (n=450) [33]
   Desire 2003-2004 75%
  France (n=555) [32]
   Expect - 33%
Perinatal Prevention Cascade
 Discussed contraception with provider
  USA [39] 2008-2010 50.6%
 Unplanned pregnancy after diagnosis
  USA [40] 2007-2009 88%
 Diagnosed before pregnancy
  USA [21, 22] 2000-2003 60%
2005-2008 68%
 Established HIV dx during pregnancy
  Italy [28] 2008 32.9%
 Use of cART in pregnancy
  USA [23] 2007-2011 85%
  Spain [7] 2004-2007 99.4%
  Italy [28] 2007-2008 95.5%
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Characteristics and countries Study period Estimates
  UK/Ireland [41] 2000-2006 82.1%
 Maternal viral suppression (undetectable)
  USA (VL >1000c/ml) [23] - 15%
  Europe [46] 2000-2010 65%
  Europe (ARV naïve) [65] 1997-2004 73%
  France [17] 2005-2008 65%
  Italy [28] 2000 37.3%
2008 80.9%
  London [47] 2000-2009 77%
  Pregnant women with VL<50
  After 3 months of tx [66] - 61.5%
  After 6 months of tx - 67.9%
 Mode of delivery: Cesarean
  USA [21, 22] 2000-2003 36%
2005-2008 40%
  Europe [46] 2000-2010 58%
  Italy [28] 2008 63.2%
  UK/Ireland [12] 1997 38.3%
1999 66.4%
2006 50%
  Spain [7] 2000-2003 57.6%
2004-2007 46.5%















 Prenatal exposure increasing
HIV-infected pregnant women:
 Age
 Numbers of pregnanciesincreasing




  Morbidity, additionaldrug exposure
 Immigration
 Poverty/housing instability
 HIV-discordant couples with seronegative women
 Contraception and family planning services, consistent access
Health-care system:
 Affordable Care Act
 Ryan White Care Program
 Local systems failures in consistently providing the full cascade of interventions
Public Health system:
 Financial support for programs
 Data
 Testing laws, state
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